



Amgen Inc.
Law Department
1201 Amgen Court West
Seattle, WA 98119

Telephone: (206) 265-7145
Facsimile: 206-233-0644

FAX MESSAGE - PLEASE DELIVER IMMEDIATELY

Send to: United States Patent Office FAX: 703-872-9306
ATTN: TC1600
Group Art Unit 1644

From: James E. Klaniecki Date: June 24, 2004
Corporate Counsel/Patent Attorney
206-265-7000 Ext. 57145

No. of pages including this page: 4

Re: US Patent Application Serial No: 10/622,237
Filed: July 17, 2003
For: MOLECULES DESIGNATED LDCAM
Our Ref.: 2873-USA

The following documents are being facsimile transmitted to the USPTO, ATTN:
TC1600:

Response to Restriction Requirement (3 pages)

If transmission problems occur contact Nanci Kertson at 206-265-7000 Ext. 57449.

CONFIDENTIALITY NOTICE: This communication (including any accompanying page(s)) is intended solely for the use of the individual or entity named above and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, you are hereby notified that any copying, distribution or other unauthorized use of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.

JUN 24 2004

Appl. No. 10/622,237
R R dated May 26, 2004
Resp. to RR dated June 24, 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Attorney Docket No.: 2873-USA

Peter Robert Baum and William Christian Fanslow, III

Serial No.: 10/622,237

Group Art Unit: 1644

Filed: July 17, 2003

Examiner: Haddad, M.

For: MOLECULES DESIGNATED LDCAM

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Introductory Comments

Responsive to the requirement to restrict mailed May 26, 2004 in connection with the above identified patent application, Applicants elect the claims of Group II, Claims 18-20, as drawn to an isolated antibody immunoreactive with LDCAM, Class 530, subclass 387.3 and 391.1.